Keywords: Erlotinib, Celecoxib, Head and neck cancer, Emory University

New drug combination could prevent head and neck cancer in high-risk patients

Article | 20 February 2013

Print This

A new drug combination shows promise in reducing the risk for patients with advanced oral precancerous lesions to develop squamous ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in